Author: Monal Sanghvi

[ad_1] Glenmark Pharma Q1 Outcomes: Revenue Falls 22%, Misses Estimates Enterprise InformationGlenmark Pharma Q1 Outcomes: Revenue Falls 22%, Misses Estimates11 Aug 2023, 6:42 PM IST 11 Aug 2023, 6:42 PM IST11 Aug 2023, 6:42 PM ISTWhatsAppTwitterFbTelegram [ad_2] Source link

[ad_1] Drugmakers To Alternate Info To Scale back Hostile FDA Inspections Enterprise InformationDrugmakers To Alternate Info To Scale back Hostile FDA Inspections22 Jun 2023, 3:49 PM IST 22 Jun 2023, 3:49 PM IST22 Jun 2023, 3:49 PM ISTWhatsAppTwitterFbTelegram [ad_2] Source link

[ad_1] Glenmark Prescribed drugs Ltd. reported flat revenue within the second quarter, however it beat estimates.The Mumbai-based bulk and generic drugmaker’s internet revenue rose 1% year-on-year to Rs 260 crore within the quarter ended September. That compares with the Rs 212-crore consensus estimate of analysts tracked by Bloomberg.Glenmark Pharma Q2 Highlights (YoY)Income rose 7% to Rs 3,375 crore towards an estimate of Rs 3,060 crore.Ebitda was up 5% at Rs 622 crore, towards the forecast of Rs 541 crore.The margin stood at 18.4% towards 18.8%. Analysts had projected it at 17.7%.In keeping with Glenn Saldanha, chairman and managing director at…